{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["P-glycoprotein", "curcumin", "doxorubicin resistance", "solid lipid nanoparticles", "triple negative breast cancer"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "31991669", "DateRevised": {"Year": "2020", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "01", "Day": "24"}], "Language": ["eng"], "ELocationID": ["96", "10.3390/pharmaceutics12020096"], "Journal": {"ISSN": "1999-4923", "JournalIssue": {"Volume": "12", "Issue": "2", "PubDate": {"Year": "2020", "Month": "Jan", "Day": "24"}}, "Title": "Pharmaceutics", "ISOAbbreviation": "Pharmaceutics"}, "ArticleTitle": "Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells.", "Abstract": {"AbstractText": ["Multidrug resistance (MDR) is a critical hindrance to the success of cancer chemotherapy. The main thing responsible for MDR phenotypes are plasma-membranes associated with adenosine triphosphate (ATP) Binding Cassette (ABC) drug efflux transporters, such as the P-glycoprotein (Pgp) transporter that has the broadest spectrum of substrates. Curcumin (CURC) is a Pgp inhibitor, but it is poorly soluble and bioavailable. To overcome these limitations, we validated the efficacy and safety of CURC, loaded in biocompatible solid lipid nanoparticles (SLNs), with or without chitosan coating, with the goal of increasing the stability, homogeneous water dispersibility, and cellular uptake. Both CURC-loaded SLNs were 5-10-fold more effective than free CURC in increasing the intracellular retention and toxicity of doxorubicin in Pgp-expressing triple negative breast cancer (TNBC). The effect was due to the decrease of intracellular reactive oxygen species, consequent inhibition of the Akt/IKK\u03b1-\u03b2/NF-kB axis, and reduced transcriptional activation of the Pgp promoter by p65/p50 NF-kB. CURC-loaded SLNs also effectively rescued the sensitivity to doxorubicin against drug-resistant TNBC tumors, without signs of systemic toxicity. These results suggest that the combination therapy, based on CURC-loaded SLNs and doxorubicin, is an effective and safe approach to overcome the Pgp-mediated chemoresistance in TNBC."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy."}, {"Identifier": [], "Affiliation": "Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El Bohouth St., 12622 Dokki, Giza, Egypt."}], "LastName": "Fathy Abd-Ellatef", "ForeName": "Gamal-Eldein", "Initials": "GE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy."}], "LastName": "Gazzano", "ForeName": "Elena", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Drug Science and Technology, via P. Giuria 9, 10125 Torino, Italy."}], "LastName": "Chirio", "ForeName": "Daniela", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry of Medicinal Plants Department, Biology Unit, Central Laboratory of Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El Bohouth St., Dokki 12622 , Giza, Egypt."}], "LastName": "Hamed", "ForeName": "Ahmed Ragab", "Initials": "AR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy."}], "LastName": "Belisario", "ForeName": "Dimas Carolina", "Initials": "DC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy."}], "LastName": "Zuddas", "ForeName": "Carlo", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Drug Science and Technology, via P. Giuria 9, 10125 Torino, Italy."}], "LastName": "Peira", "ForeName": "Elena", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Drug Science and Technology, via P. Giuria 9, 10125 Torino, Italy."}], "LastName": "Rolando", "ForeName": "Barbara", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy."}], "LastName": "Kopecka", "ForeName": "Joanna", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science, Cairo University, Gamaa Street, Dokki 12622 , Giza, Egypt."}], "LastName": "Assem Said Marie", "ForeName": "Mohamed", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Drug Science and Technology, via P. Giuria 9, 10125 Torino, Italy."}], "LastName": "Sapino", "ForeName": "Simona", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science, Cairo University, Gamaa Street, Dokki 12622 , Giza, Egypt."}], "LastName": "Ramadan Fahmy", "ForeName": "Sohair", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El Bohouth St., 12622 Dokki, Giza, Egypt."}], "LastName": "Gallarate", "ForeName": "Marina", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El Bohouth St., 12622 Dokki, Giza, Egypt."}], "LastName": "Abdel-Hamid", "ForeName": "Abdel-Hamid Zaki", "Initials": "AZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy."}], "LastName": "Riganti", "ForeName": "Chiara", "Initials": "C"}], "GrantList": [{"GrantID": "IG21408", "Agency": "Associazione Italiana per la Ricerca sul Cancro", "Country": ""}, {"GrantID": "CA17104", "Agency": "European Cooperation in Science and Technology", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceutics", "NlmUniqueID": "101534003", "ISSNLinking": "1999-4923"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Chen Z., Shi T., Zhang L., Zhu P., Deng M., Huang C., Hu T., Jiang L., Li J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016;370:153\u2013164. doi: 10.1016/j.canlet.2015.10.010.", "ArticleIdList": ["10.1016/j.canlet.2015.10.010", "26499806"]}, {"Citation": "Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer. 2013;13:714\u2013726. doi: 10.1038/nrc3599.", "ArticleIdList": ["10.1038/nrc3599", "24060863"]}, {"Citation": "Ween M.P., Armstrong M.A., Oehler M.K., Ricciardelli C. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit. Rev. Oncol. Hematol. 2015;96:220\u2013256. doi: 10.1016/j.critrevonc.2015.05.012.", "ArticleIdList": ["10.1016/j.critrevonc.2015.05.012", "26100653"]}, {"Citation": "Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: Role of ATP\u2013dependent transporters. Nat. Rev. Cancer. 2002;2:48\u201358. doi: 10.1038/nrc706.", "ArticleIdList": ["10.1038/nrc706", "11902585"]}, {"Citation": "Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist. Update. 2011;14:150\u2013163. doi: 10.1016/j.drup.2011.01.003.", "ArticleIdList": ["10.1016/j.drup.2011.01.003", "21330184"]}, {"Citation": "Stuart E.C., Jarvis R.M., Rosengren R.J. In Vitro mechanism of action for the cytotoxicity elicited by the combination of epigallocatechin gallate and raloxifene in MDA-MB-231 cells. Oncol. Rep. 2010;24:779\u2013785. doi: 10.3892/or_00000921.", "ArticleIdList": ["10.3892/or_00000921", "20664987"]}, {"Citation": "Lehmann B.D., Jovanovi\u0107 B., Chen X., Estrada M.V., Johnson K.N., Shyr Y., Moses H.L., Sanders M.E., Pietenpol J.A. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE. 2016;11:e0157368. doi: 10.1371/journal.pone.0157368.", "ArticleIdList": ["10.1371/journal.pone.0157368", "PMC4911051", "27310713"]}, {"Citation": "Willers C., Svitina H., Rossouw M.J., Swanepoel R.A., Hamman J.H., Gouws C. Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux. J. Cancer Res. Clin. Oncol. 2019;145:1949\u20131976. doi: 10.1007/s00432-019-02973-5.", "ArticleIdList": ["10.1007/s00432-019-02973-5", "31292714"]}, {"Citation": "Wu Q., Yang Z., Nie Y., Shi Y., Fan D. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 2014;347:159\u2013166. doi: 10.1016/j.canlet.2014.03.013.", "ArticleIdList": ["10.1016/j.canlet.2014.03.013", "24657660"]}, {"Citation": "Szak\u00e1cs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006;5:219\u2013234. doi: 10.1038/nrd1984.", "ArticleIdList": ["10.1038/nrd1984", "16518375"]}, {"Citation": "Zinzi L., Capparelli E., Cantore M., Contino M., Leopoldo M., Colabufo N.A. Small and Innovative Molecules as New Strategy to Revert MDR. Front. Oncol. 2014;4:1\u201312. doi: 10.3389/fonc.2014.00002.", "ArticleIdList": ["10.3389/fonc.2014.00002", "PMC3896858", "24478983"]}, {"Citation": "Hu C.M.J., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012;83:1104\u20131111. doi: 10.1016/j.bcp.2012.01.008.", "ArticleIdList": ["10.1016/j.bcp.2012.01.008", "22285912"]}, {"Citation": "Limtrakul P., Anuchapreeda S., Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcumoids. BMC Cancer. 2004;4:13. doi: 10.1186/1471-2407-4-13.", "ArticleIdList": ["10.1186/1471-2407-4-13", "PMC404465", "15090070"]}, {"Citation": "Lopes-Rodrigues V., Sousa E., Vasconcelos M.H. Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives. Pharmaceuticals. 2016;9:71. doi: 10.3390/ph9040071.", "ArticleIdList": ["10.3390/ph9040071", "PMC5198046", "27834897"]}, {"Citation": "Yallapu M.M., Jaggi M., Chauhan S.C. Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discov. Today. 2012;17:71\u201380. doi: 10.1016/j.drudis.2011.09.009.", "ArticleIdList": ["10.1016/j.drudis.2011.09.009", "PMC3259195", "21959306"]}, {"Citation": "Yallapu M.M., Jaggi M., Chauhan S.C. Curcumin nanomedicine: A road to cancer therapeutics. Curr. Pharm. Des. 2013;19:1994\u20132010. doi: 10.2174/138161213805289219.", "ArticleIdList": ["10.2174/138161213805289219", "PMC3640558", "23116309"]}, {"Citation": "Guri A., G\u00fclseren I., Corredig M. Utilization of solid lipid nanoparticles for enhanced delivery of CURC in cocultures of HT29-MTX and Caco-2 cells. Food Funct. 2013;4:1410\u20131419. doi: 10.1039/c3fo60180c.", "ArticleIdList": ["10.1039/c3fo60180c", "23921424"]}, {"Citation": "Nakhlband A., Eskandani M., Saeedi N., Ghafari S., Omidi Y., Barar J., Garjani A. Marrubiin-loaded solid lipid nanoparticles\u2019 impact on TNF-\u03b1 treated umbilical vein endothelial cells: A study for cardioprotective effect. Colloids Surf. B Biointerfaces. 2018;164:299\u2013307. doi: 10.1016/j.colsurfb.2018.01.046.", "ArticleIdList": ["10.1016/j.colsurfb.2018.01.046", "29413609"]}, {"Citation": "Rehman M.U., Khan M.A., Khan W.S., Shafique M., Khan M. Fabrication of Niclosamide loaded solid lipid nanoparticles: In Vitro characterization and comparative in vivo evaluation. Artif. Cells Nanomed. Biotechnol. 2018;46:1926\u20131934. doi: 10.1080/21691401.2017.1396996.", "ArticleIdList": ["10.1080/21691401.2017.1396996", "29113501"]}, {"Citation": "Baek J.S., Na Y.G., Cho C.W. Sustained cytotoxicity of wogonin on breast cancer cells by encapsulation in solid lipid nanoparticles. Nanomaterials. 2018;8:159. doi: 10.3390/nano8030159.", "ArticleIdList": ["10.3390/nano8030159", "PMC5869650", "29533979"]}, {"Citation": "Wang W., Chen T., Xu H., Ren B., Cheng X., Qi R., Liu H., Wang Y., Yan L., Chen S., et al. Curcumin-loaded solid lipid nanoparticles enhanced anticancer efficiency in breast cancer. Molecules. 2018;23:1587. doi: 10.3390/molecules23071578.", "ArticleIdList": ["10.3390/molecules23071578", "PMC6099699", "29966245"]}, {"Citation": "Agnihotri S.A., Mallikarjuna N.N., Aminabhavi T.M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release. 2004;100:5\u201328. doi: 10.1016/j.jconrel.2004.08.010.", "ArticleIdList": ["10.1016/j.jconrel.2004.08.010", "15491807"]}, {"Citation": "Chirio D., Peira E., Sapino S., Dianzani C., Barge A., Muntoni E., Morel S., Gallarate M. Stearoyl-chitosan coated nanoparticles obtained by microemulsion cold dilution technique. Int. J. Mol. Sci. 2018;19:3833. doi: 10.3390/ijms19123833.", "ArticleIdList": ["10.3390/ijms19123833", "PMC6321505", "30513699"]}, {"Citation": "Chirio D., Peira E., Dianzani C., Muntoni E., Gigliotti C.L., Ferrara B., Sapino S., Chindamo G., Gallarate M. Development of Solid Lipid Nanoparticles by Cold Dilution of Microemulsions: CURC Loading, Preliminary In Vitro Studies, and Biodistribution. Nanomaterials. 2019;9:230. doi: 10.3390/nano9020230.", "ArticleIdList": ["10.3390/nano9020230", "PMC6410061", "30744025"]}, {"Citation": "Yuan S., Dong Y., Peng L., Yang M., Niu L., Liu Z., Xie J. Tumor-associated macrophages affect the biological behavior of lung adenocarcinoma A549 cells through the PI3K/AKT signaling pathway. Oncol. Lett. 2019;18:1840\u20131846. doi: 10.3892/ol.2019.10483.", "ArticleIdList": ["10.3892/ol.2019.10483", "PMC6607053", "31423252"]}, {"Citation": "Long L., Yin M., Min W. 3D Co-culture System of Tumor-associated Macrophages and Ovarian Cancer Cells. Bio. Protoc. 2018;8:E2815. doi: 10.21769/BioProtoc.2815.", "ArticleIdList": ["10.21769/BioProtoc.2815", "PMC5951403", "29770354"]}, {"Citation": "Riganti C., Miraglia E., Viarisio D., Costamagna C., Pescarmona G., Ghigo D., Bosia A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 2005;65:516\u2013525.", "ArticleIdList": ["15695394"]}, {"Citation": "Riganti C., Costamagna C., Doublier S., Miraglia E., Polimeni M., Bosia A., Ghigo D. The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicol. Appl. Pharmacol. 2008;228:277\u2013285. doi: 10.1016/j.taap.2007.12.013.", "ArticleIdList": ["10.1016/j.taap.2007.12.013", "18234259"]}, {"Citation": "Riganti C., Voena C., Kopecka J., Corsetto P.A., Montorfano G., Enrico E., Costamagna C., Rizzo A.M., Ghigo D., Bosia A. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol. Pharm. 2011;8:683\u2013700. doi: 10.1021/mp2001389.", "ArticleIdList": ["10.1021/mp2001389", "21491921"]}, {"Citation": "Riganti C., Gazzano E., Gulino G.R., Volante M., Ghigo D., Kopecka J. Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. Cancer Lett. 2015;360:219\u2013226. doi: 10.1016/j.canlet.2015.02.008.", "ArticleIdList": ["10.1016/j.canlet.2015.02.008", "25681670"]}, {"Citation": "Gazzano E., Rolando B., Chegaev K., Salaroglio I.C., Kopecka J., Pedrini I., Saponara S., Sorge M., Buondonno I., Stella B., et al. Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. J. Control. Release. 2018;270:37\u201352. doi: 10.1016/j.jconrel.2017.11.042.", "ArticleIdList": ["10.1016/j.jconrel.2017.11.042", "29191785"]}, {"Citation": "Kopecka J., Salzano G., Campia I., Lusa S., Ghigo E., De Rosa G., Riganti C. Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. Nanomedicine. 2014;10:77\u201387. doi: 10.1016/j.nano.2013.06.013.", "ArticleIdList": ["10.1016/j.nano.2013.06.013", "23850894"]}, {"Citation": "Kopecka J., Campia I., Jacobs A., Frei A.P., Ghigo D., Wollscheid B., Riganti C. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget. 2015;6:6776\u20136793. doi: 10.18632/oncotarget.2882.", "ArticleIdList": ["10.18632/oncotarget.2882", "PMC4466649", "25686827"]}, {"Citation": "Kim S.Y., Kim S.J., Kim B.J., Rah S.Y., Chung S.M., Im M.J., Kim U.H. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp. Mol. Med. 2006;38:535\u2013545. doi: 10.1038/emm.2006.63.", "ArticleIdList": ["10.1038/emm.2006.63", "17079870"]}, {"Citation": "Pilco-Ferreto N., Calaf G.M. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int. J. Oncol. 2016;49:753\u2013762. doi: 10.3892/ijo.2016.3558.", "ArticleIdList": ["10.3892/ijo.2016.3558", "27278553"]}, {"Citation": "Mohajeri M., Sahebkar A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review. Crit. Rev. Oncol. Hematol. 2018;122:30\u201351. doi: 10.1016/j.critrevonc.2017.12.005.", "ArticleIdList": ["10.1016/j.critrevonc.2017.12.005", "29458788"]}, {"Citation": "Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387\u20133394.", "ArticleIdList": ["12067980"]}, {"Citation": "Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., Gielen J., Merville M.P., Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22:90\u201397. doi: 10.1038/sj.onc.1206056.", "ArticleIdList": ["10.1038/sj.onc.1206056", "12527911"]}, {"Citation": "Karabay A.Z., Koc A., Ozkan T., Hekmatshoar Y., Altinok Gunes B., Sunguroglu A., Buyukbingol Z., Atalay A., Aktan F. Expression analysis of Akirin-2, NF\u03baB-p65 and \u03b2-catenin proteins in imatinib resistance of chronic myeloid leukemia. Hematology. 2018;23:765\u2013770. doi: 10.1080/10245332.2018.1488795.", "ArticleIdList": ["10.1080/10245332.2018.1488795", "29945498"]}, {"Citation": "Orlowski R.Z., Baldwin A.S. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 2002;8:385\u2013389. doi: 10.1016/S1471-4914(02)02375-4.", "ArticleIdList": ["10.1016/S1471-4914(02)02375-4", "12127724"]}, {"Citation": "Christian F., Smith E., Carmody R. The Regulation of NF-\u03baB Subunits by Phosphorylation. Cells. 2016;5:23. doi: 10.3390/cells5010012.", "ArticleIdList": ["10.3390/cells5010012", "PMC4810097", "26999213"]}, {"Citation": "Hinz M., Arslan S.\u00c7., Scheidereit C. It takes two to tango: I\u03baBs, the multifunctional partners of NF-\u03baB. Immunol. Rev. 2012;246:59\u201376. doi: 10.1111/j.1600-065X.2012.01102.x.", "ArticleIdList": ["10.1111/j.1600-065X.2012.01102.x", "22435547"]}, {"Citation": "Isra\u00ebl A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb. Perspect. Biol. 2010;2:a000158. doi: 10.1101/cshperspect.a000158.", "ArticleIdList": ["10.1101/cshperspect.a000158", "PMC2829958", "20300203"]}, {"Citation": "Zhao Y., Hu X., Liu Y., Dong S., Wen Z., He W., Zhang S., Huang Q., Shi M. ROS signaling under metabolic stress: Cross-talk between AMPK and AKT pathway. Mol. Cancer. 2017;16:79. doi: 10.1186/s12943-017-0648-1.", "ArticleIdList": ["10.1186/s12943-017-0648-1", "PMC5390360", "28407774"]}, {"Citation": "Liu C., He X., Liu X., Yu J., Zhang M., Yu F., Wang Y. RPS15A promotes gastric cancer progression via activation of the Akt/IKK-\u03b2/NF-\u03baB signalling pathway. J. Cell Mol. Med. 2019;23:2207\u20132218. doi: 10.1111/jcmm.14141.", "ArticleIdList": ["10.1111/jcmm.14141", "PMC6378197", "30661291"]}, {"Citation": "Yin Y., Yao S., Hu Y., Feng Y., Li M., Bian Z., Zhang J., Qin Y., Qi X., Zhou L., et al. The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6. Clin. Cancer Res. 2017;23:7375\u20137387. doi: 10.1158/1078-0432.CCR-17-1283.", "ArticleIdList": ["10.1158/1078-0432.CCR-17-1283", "28928161"]}, {"Citation": "Genin M., Clement F., Fattaccioli A., Raes M., Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:E577. doi: 10.1186/s12885-015-1546-9.", "ArticleIdList": ["10.1186/s12885-015-1546-9", "PMC4545815", "26253167"]}, {"Citation": "Llano S., G\u00f3mez S., Londo\u00f1o J., Restrepo A. Antioxidant activity of curcumoids. Phys. Chem. Chem. Phys. 2019;21:3752\u20133760. doi: 10.1039/C8CP06708B.", "ArticleIdList": ["10.1039/C8CP06708B", "30702098"]}, {"Citation": "Menon V.P., Sudheer A.R. Antioxidant and anti-inflammatory properties of curcumi. Adv. Exp. Med. Biol. 2014;595:105\u2013125. doi: 10.1007/978-0-387-46401-5_3.", "ArticleIdList": ["10.1007/978-0-387-46401-5_3", "17569207"]}, {"Citation": "Moghadamtousi Z.S., Abdul Kadir H., Hassandarvish P., Tajik H., Abubakar S., Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res. Int. 2014;2014:1\u201312. doi: 10.1155/2014/186864.", "ArticleIdList": ["10.1155/2014/186864", "PMC4022204", "24877064"]}, {"Citation": "L\u00f3pez-L\u00e1zaro M. Anticancer and carcinogenic properties of curcumin: Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res. 2008;52:103\u2013127. doi: 10.1002/mnfr.200700238.", "ArticleIdList": ["10.1002/mnfr.200700238", "18496811"]}, {"Citation": "Guerrero S., Inostroza-Riquelme M., Contreras-Orellana P., Diaz-Garcia V., Lara P., Vivanco-Palma A., C\u00e1rdenas A., Miranda V., Robert P., Leyton L., et al. Curcumin-loaded nanoemulsion: A new safe and effective formulation to prevent tumor reincidence and metastasis. Nanoscale. 2018;10:22612\u201322622. doi: 10.1039/C8NR06173D.", "ArticleIdList": ["10.1039/C8NR06173D", "30484463"]}, {"Citation": "Vallianou N.G., Evangelopoulos A., Schizas N., Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 2015;35:645\u2013651.", "ArticleIdList": ["25667441"]}, {"Citation": "Sun J., Bi C., Chan H.M., Sun S., Zhang Q., Zheng Y. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Colloids Surf. B Biointerfaces. 2013;111:367\u2013375. doi: 10.1016/j.colsurfb.2013.06.032.", "ArticleIdList": ["10.1016/j.colsurfb.2013.06.032", "23856543"]}, {"Citation": "Lu Y., Li F., Xu T., Sun J. Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-\u03baB signaling. Int. J. Mol. Med. 2017;39:993\u20131000. doi: 10.3892/ijmm.2017.2895.", "ArticleIdList": ["10.3892/ijmm.2017.2895", "28260091"]}, {"Citation": "Movafagh S., Crook S., Vo K. Regulation of hypoxia-inducible factor-1a by reactive oxygen species: New developments in an old debate. J. Cell Biochem. 2015;116:696\u2013703. doi: 10.1002/jcb.25074.", "ArticleIdList": ["10.1002/jcb.25074", "25546605"]}, {"Citation": "Zhang J., Wang X., Vikash V., Ye Q., Wu D., Liu Y., Dong W. ROS and ROS-Mediated Cellular Signaling. Oxid. Med. Cell Longev. 2016;2016:4350965. doi: 10.1155/2016/4350965.", "ArticleIdList": ["10.1155/2016/4350965", "PMC4779832", "26998193"]}, {"Citation": "Hossain M.M., Banik N.L., Ray S.K. Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem. Int. 2012;61:1102\u20131113. doi: 10.1016/j.neuint.2012.08.002.", "ArticleIdList": ["10.1016/j.neuint.2012.08.002", "PMC3508157", "22910273"]}, {"Citation": "Komohara Y., Takeya M. CAFs and TAMs: Maestros of the tumour microenvironment. J. Pathol. 2017;241:313\u2013315. doi: 10.1002/path.4824.", "ArticleIdList": ["10.1002/path.4824", "27753093"]}, {"Citation": "Callaghan R., Luk F., Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: Time for a change of strategy? Drug Metab. Dispos. 2014;42:623\u2013631. doi: 10.1124/dmd.113.056176.", "ArticleIdList": ["10.1124/dmd.113.056176", "PMC3965902", "24492893"]}, {"Citation": "Sz\u00e9kely B., Silber A.L.M., Pusztai L. New Therapeutic Strategies for Triple-Negative Breast Cancer. Oncology. 2017;31:130\u2013137.", "ArticleIdList": ["28205193"]}, {"Citation": "Salaroglio I.C., Gazzano E., Abdullrahman A., Mungo E., Castella B., Abd-Elrahman G.E.F.A., Massaia M., Donadelli M., Rubinstein M., Riganti C., et al. Increasing intratumor C/EBP-\u03b2 LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J. Exp. Clin. Cancer Res. 2018;37:286. doi: 10.1186/s13046-018-0967-0.", "ArticleIdList": ["10.1186/s13046-018-0967-0", "PMC6258159", "30482226"]}]}], "History": [{"Year": "2019", "Month": "12", "Day": "10"}, {"Year": "2020", "Month": "1", "Day": "16"}, {"Year": "2020", "Month": "1", "Day": "21"}, {"Year": "2020", "Month": "1", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "30", "Hour": "6", "Minute": "1"}, {"Year": "2020", "Month": "2", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["31991669", "PMC7076516", "10.3390/pharmaceutics12020096", "pharmaceutics12020096"]}}]}